Idiosyncratic drug-induced liver injury: a clinical update (Q37806980)

23 August 2017

title

Idiosyncratic drug-induced liver injury: a clinical update (English)

1 reference

23 August 2017

Haripriya Maddur

1

1 reference

23 August 2017

Naga Chalasani

series ordinal

2

1 reference

23 August 2017

publication date

1 February 2011

1 reference

Current gastroenterology reports

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

65-71

1 reference

Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Epidemiology and individual susceptibility to adverse drug reactions affecting the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Severe liver injury after initiating therapy with atomoxetine in two children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Risk factors for idiosyncratic drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Clinical syndromes and consequences of antiretroviral-related hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Idiosyncratic drug reactions: current understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Drug-induced liver injury following positive drug rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

The role of hepatitis E virus testing in drug-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Drug-induced liver injury: Hy's rule revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-010-0154-8

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

21 January 2018

1 reference

12 December 2020

Autoimmune hepatitis triggered by statins

1 reference

12 December 2020

Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge

1 reference

12 December 2020

An assessment of statin safety by hepatologists

1 reference

12 December 2020

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

1 reference

12 December 2020

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period

1 reference

12 December 2020

10.1007/S11894-010-0154-8

Identifiers

DOI

1 reference

23 August 2017

1 reference